Immunome, Inc. has grown revenue 26% a year over three years and 1016% a year over five. Revenue growth, 3-year annual rate: +26% (Biotechnology median +17%). Revenue growth, 5-year rate: +1016%, growth has slowed since the five-year average. Years of annual history on file: 7, FY2019 to FY2025, as filed.

IMNMImmunome, Inc.

Healthcare

$19.56+108% 1Y

$19.56

$9.7752 weeks$29.84

Is it growing?

Mixed

Revenue roughly flat (+5% year on year). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 neutral, 2 without data

Revenue trend+5% in a yearSEC EDGAR · Jun 30, 2026

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is IMNM growing?

Immunome, Inc. has grown revenue 26% a year over three years and 1016% a year over five.

+26%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +1016%
Revenue growth, 5-year rate · +26% over three · growth has slowed since the five-year average
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›